Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

This study has been terminated.
(The study was terminated due to a company decision following completion of Part A.)
Molecular Partners AG
Information provided by (Responsible Party):
Allergan Identifier:
First received: March 9, 2010
Last updated: November 21, 2011
Last verified: November 2011

The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with wet Age Related Macular Degeneration.

Condition Intervention Phase
Wet Age-Related Macular Degeneration
Biological: MP0112
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Safety and tolerability, Safety assessments will be done for 16 weeks after intraocular injection of MP0112. [ Time Frame: 16 weeks ] [ Designated as safety issue: Yes ]
    1. Determination of the maximal tolerated dose (MTD) following a single injection (Part A only)
    2. All ocular and systemic adverse events, including serious adverse events whether related or not to study treatment or study procedures
    3. Vital signs, as well as the haematological and blood chemistry laboratory values after treatment as compared with their values before treatment.

Secondary Outcome Measures:
  • The change from baseline in best-corrected visual acuity (BCVA) over 16 weeks after injection of MP0112. [ Time Frame: Baseline, 16 weeks ] [ Designated as safety issue: No ]

Enrollment: 32
Study Start Date: March 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: MP0112

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical signs and angiographic evidence of active primary progressive subfoveal choroidal neovascularisation (CNV), including juxtafoveal lesions that affect the fovea on FA in the study eye that is at least 50% of the total lesion area
  • ETDRS best-corrected visual acuity of: 20/40 to 20/320 in the study eye at 4 meters
  • Male or female age > 50 years
  • Written informed consent prior to any study procedures
  • Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.

Exclusion Criteria:

  • Prior treatment with anti-VEGF therapy in the study eye, including bevacizumab, ranibizumab, or pegaptanib, as well as photodynamic therapy with verteporfin
  • Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins
  • Subfoveal thermal laser therapy, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
  • Extrafoveal laser coagulation treatment within 12 weeks prior to Baseline in the study eye
  • Total lesion size > 20mm2 (including blood, scars and neovascularization) as assessed by FA in the study eye
  • Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 2.54mm2 or more in size in the study eye
  • Scar or fibrosis, making up > 50% of total lesion in the study eye
  • Scar, fibrosis, or atrophy involving the center of the fovea
  • Presence of retinal pigment epithelial tears or rips
  • History of any vitreous hemorrhage within 4 weeks prior to Visit 1 or current hemorrhage in the study eye
  • Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye
  • History or clinical evidence of diabetic retinopathy, diabetic macular oedema or any other vascular disease affecting the retina, other than AMD, in either eye
  • Prior vitrectomy in the study eye
  • History of retinal detachment or treatment or surgery for retinal detachment in the study eye
  • Ocular surgery (including cataract removal) in the study eye within 3 months of enrolment
  • Active intraocular inflammation (grade trace or above) in the study eye
  • History of allergy to any components of the study drug or diagnostic devices, such as fluorescein
  • Advanced glaucoma or intraocular pressure above 22 mmHg in the study eye despite treatment
  • Inability to obtain fundus photographs or fluorescein angiogram of sufficient quality to be analyzed and graded by the central reading center
  • History of idiopathic or autoimmune-associated uveitis in either eye
  • Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Aphakia or absence of the posterior capsule in the study eye
  • Presence of a non-healing wound, ulcer, fracture or any other medical condition associated with bleeding
  • Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of enrolment
  • Premenopausal women
  • Any disorder or condition that contraindicates the use of an investigational drug
  • Participation in another investigational drug study within 3 months of enrolment
  • Uncontrolled hypertension
  • Previous stroke within 12 months of study entry
  • Systemic treatment with any anti-VEGF drug
  • Current treatment for active systemic infection
  Contacts and Locations
Please refer to this study by its identifier: NCT01086761

Czech Republic
Fakultni Nemocnice Brno
Brno, Czech, Czech Republic, 62500
Fakultni Nemocnice Olomouc
Olomouc, Czech, Czech Republic, 77520
Ustrendi Vojenska Nemocnice
Praha, Czech, Czech Republic, 16902
Unité Médicale Rétine, Uvéites, Neuro-Ophtalmologie Service d'Ophtalmologie, Hôpital Pellegrin
Bordeaux, France, 33000
Hopital Intercommunual de Creteil
Creteil, France, 94010
Centre Rabelais
Lyon, France, 69003
Centre Paradis-Monticelli
Marseille, France, 13008
Hopitaux Universitaires
Strasbourg, France, 67091
Bern, Switzerland, CH-3010
Sponsors and Collaborators
Molecular Partners AG
  More Information

No publications provided

Responsible Party: Allergan Identifier: NCT01086761     History of Changes
Other Study ID Numbers: MP0112-CP01
Study First Received: March 9, 2010
Last Updated: November 21, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Czech Republic: State Institute for Drug Control
Switzerland: Swissmedic

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases processed this record on April 17, 2014